连接政策与创新:SPARC-Europe对癌症放射性配体治疗的愿景
该联盟已发布关于改善RLT可及性的高级别立场文件、基础设施投资路径文件、患者证言视频,举办两次政策活动,并支持欧洲议会关于放射性核素供应和医院基础设施投资的决议动议。其正在开展RADAR全球调查,评估神经内分泌肿瘤和前列腺癌患者及医生对RLT的认知、可及性和看法。
要点
- SPARC-Europe是多利益相关方联盟,致力于将RLT制度化以改善欧洲癌症患者结局。
- 已产出立场文件、投资路径文件、患者证言视频并支持欧洲议会决议动议。
- 正在开展RADAR全球调查,聚焦神经内分泌肿瘤和前列腺癌的RLT认知与可及性。
核心结论
- SPARC-Europe通过整合政策、科学与患者倡导,支持RLT创新并塑造其交付框架。
主要发现
- 已发布关于改善RLT可及性的高级别立场文件和指导基础设施发展的投资路径文件。
- 录制了患者证言视频以人性化展示扩大可及性的需求,并组织了两次专门针对RLT的政策活动。
- 支持了欧洲议会呼吁投资放射性核素供应和医院基础设施的决议动议。
- 正在开展RADAR全球调查,聚焦神经内分泌肿瘤和前列腺癌,评估患者和医生对RLT的认知、可及性和看法。
临床怎么用
- 核医学科可关注SPARC-Europe的政策文件与RADAR调查结果,以了解RLT可及性和认知现状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SPARC-Europe, the Stakeholder Political Alliance for Radioligand Cancer Therapies, was launched in October 2020. It represents an ambitious and collaborative initiative aimed at improving outcomes for cancer patients across Europe by advancing the policy and infrastructure needed to institutionalize Radioligand Therapies (RLTs). The current steering committee comprises several types of health care professionals, such as nuclear medicine specialists, clinicians, nurses, physicists, radio-pharmacists, and patient advocates, under a shared vision. Since its inception, SPARC-Europe has achieved several notable milestones, including the publication of a high-level position paper on improving access to RLTs., the production of an investment pathway document to guide infrastructure development, the recording of compelling patient testimony videos to humanize the need for expanded access, the organization of two influential policy events dedicated to RLTs, the support of motions for resolutions in the European Parliament that call for investments in radionuclide supply and hospital infrastructure. SPARC-Europe is continuing to deepen its work through targeted research and pilot programs, including the RADAR (Radioligand Awareness Research), a global survey focused on neuroendocrine neoplasms and prostate cancer to assess awareness, accessibility, and perceptions of RLTs among patients and physicians. By bringing together policy, science, and patient advocacy, SPARC-Europe is not only supporting innovation but actively shaping the frameworks needed to deliver it to those who need it most. As the European health landscape continues to evolve, SPARC-Europe offers a model for how patient-centered, evidence-based, and policy-savvy coalitions can drive meaningful change.
引用
- Fazio N, Gasset IC, Hermann K, et al. Bridging policy and innovation: SPARC-Europe's vision for radioligand therapy in cancer care. Eur J Nucl Med Mol Imaging. 2025. PMID: 40974406. doi:10.1007/s00259-025-07534-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。